VELDONA Pet will hit shelves in Taiwan in June, with launches in other regions to follow
Multiple new VELDONA Pet products set to launch as Ainos enters the growing global pet care market
SAN DIEGO, CA / ACCESSWIRE / May 30, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has launched its VELDONA Pet cytoprotein health supplements. VELDONA Pet will first be marketed in Taiwan in June, with near-term plans to expand sales and marketing in other markets. Multiple new VELDONA Pet products are in the works. Ainos targets approximately US$20 million in revenues from VELDONA Pet during 2024, boosted by its growing product portfolio and expansion into new markets.
Chun-Hsien Tsai, Ainos' Chairman of the Board, President, and Chief Executive Officer, commented, "The second half of 2023 will be a very exciting period for Ainos. There is a huge addressable market for our product: China has around 117 million pet dogs and cats, Japan has approximately 18 million, and the U.S. has 190 million. We expect that VELDONA Pet products will position us to capture the lucrative global pet care market, which is projected to grow to over US$325 billion in 2028 from US$223 billion in 2021, according to Fortune Business Insights."
"We are developing multiple new products based on VELDONA Pet to provide pet owners with more innovative options to support their pets' health," Mr. Tsai said. "Boosted by our growing product portfolio and expansion into new markets, our ambition is that VELDONA Pet will generate approximately US$20 million in revenues during 2024."
"The introduction of Ainos' VELDONA Pet health supplements in Taiwan marks the beginning of a new chapter in our company's story," Mr. Tsai added. "We leveraged 40 years of interferon research to develop VELDONA Pet, which now serves as a vital component of our next stage of growth. The fact that we were able to bring it to market a quarter ahead of schedule is yet another testament to our team's unparalleled expertise and ability to execute."
"We expect VELDONA Pet to be available for sale in Taiwan in June. With approximately one in four Taiwanese families now owning pets, Taiwan is the ideal location for our product launch. There are currently around three million pet dogs and cats in Taiwan, surpassing the number of children under 14 years old, and this number is projected to grow to four million by 2025.
VELDONA Pet 將於 6 月在中國臺灣上架，隨後將在其他地區上市
隨着Ainos進入不斷增長的全球寵物護理市場，將推出多款新的VELDONA Pet產品
加利福尼亞州聖地亞哥/ACCESSWIRE/2023 年 5 月 30 日/ 專注於開發新型即時檢測、低劑量干擾素療法和合成RNA驅動的預防藥物的多元化醫療科技公司Ainos, Inc.（納斯達克股票代碼：AIMD，AIMDW）（“Ainos” 或 “公司”）今天宣佈已推出VELDONA Pet細胞蛋白健康補充劑。VELDONA Pet 將於6月在中國臺灣首次上市，短期內計劃擴大在其他市場的銷售和營銷。多款新的 VELDONA Pet 產品正在開發中。Ainos的目標是在2024年從VELDONA Pet獲得約2000萬美元的收入，這得益於其不斷增長的產品組合和向新市場的擴張。
Ainos董事會主席、總裁兼首席執行官蔡春賢評論說：“對於Ainos來說，2023年下半年將是一個非常激動人心的時期。我們的產品有巨大的潛在市場：中國有大約1.17億隻寵物狗和貓，日本有大約1800萬隻，美國有1.9億隻。根據《財富商業洞察》，我們預計VELDONA寵物產品將使我們能夠佔領利潤豐厚的全球寵物護理市場，預計該市場將從2021年的2,23億美元增長到2028年的3,250億美元以上。”
蔡先生說：“我們正在開發多種基於VELDONA Pet的新產品，爲寵物主人提供更多創新的選擇，以支持他們的寵物的健康。”“在我們不斷增長的產品組合和向新市場的擴張的推動下，我們的目標是讓VELDONA Pet在2024年創造約2000萬美元的收入。”
蔡先生補充說：“Ainos的VELDONA寵物保健品在臺灣的推出標誌着我們公司故事的新篇章的開始。”“我們利用40年的干擾素研究開發了VELDONA Pet，它現在已成爲我們下一階段增長的重要組成部分。我們能夠提前一個季度將其推向市場，這一事實再次證明了我們團隊無與倫比的專業知識和執行能力。”
“我們預計 VELDONA Pet 將於 6 月在臺灣上市。現在，大約四分之一的臺灣家庭擁有寵物，臺灣是我們產品發佈的理想地點。目前，臺灣大約有300萬隻寵物狗和貓，超過了14歲以下兒童的人數，預計到2025年這一數字將增長到400萬。
